Life Sciences

What we have learned from the early years of biosimilar litigation

IAM looks at the trends – in terms of the patent dance, IP thickets, settlements and decisions – that have shaped US disputes so far

What we have learned from the early years of biosimilar litigation
9 Dec 2019

Healthcare and pharma sector sees most patent deals activity in Q3 in the US 

Latest data shows Global Foundries, IV and Seiko among top sellers; NPEs the top buyers, with Samsung, Pinterest and BBK Electronics also among the leaders

9 Dec 2019

Examination agreement between Japan and India steers clear of life sciences

The two countries inaugurated a Patent Prosecution Highway scheme last week, but it will be one-way traffic when it comes to pharma rights

Latest

View all
6 Dec 2019

Fish & Richardson tops list of firms that the US patent elite use for litigation

More than half the companies that make up the IAM/ktMINE listing of the entities with the biggest US portfolios have instructed Fish lawyers to represent them in district court disputes over the course of the last decade Read more

5 Dec 2019

Biologics exclusivity may be sacrificed to seal NAFTA 2.0 deal

Trump administration said to be considering weakening provisions to break political gridlock over USMCA Read more

5 Dec 2019

The search for the world's leading IP strategists is on

IAM is currently seeking nominations for individuals to be considered for the 2020 edition of the Strategy 300 - our unique guide to the men and women who excel in the creation of IP value Read more

4 Dec 2019

What leaked US trade talks tell us about future of UK pharma IP

Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month Read more

News

View all
25 Nov 2019

Three hidden issues that could affect your China IP transaction

Cross-border deals face regulatory risks that go beyond IP law Read more

18 Nov 2019

South Africa's top court issues first patent decision but fails to clarify infringement defence uncertainties

The country’s Constitutional Court, which split down the middle, refused to grant an appeal to challenge a Merck patent on new grounds Read more

8 Nov 2019

Catch up on the most important life sciences IP developments from the past month

Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019 Read more

8 Nov 2019

A snapshot of the global patent landscape in eight charts  

A recently issued WIPO report based on multiple data points sheds light on the state of play in worldwide patenting activity Read more

Analysis

View all
28 Nov 2019

Four IP takeaways from Novartis’ $9.7 billion acquisition of The Medicines Company

Over the weekend, Novartis struck one of the largest deals in the biopharma sectors this year, agreeing to pay $9.7 billion for cardiovascular specialist The Medicines Company Read more

27 Nov 2019

FDA takes rare step of revoking orphan drug status

The decision means that Indivior’s Sublocade is no longer eligible for lucrative exclusivity, but leaves concerns about evergreening unaddressed Read more

21 Nov 2019

US Presidential hopefuls set their sights on pharma patents

With several leading Democratic candidates threatening to circumvent pharma IP, next year’s election could prove pivotal for right owners Read more

19 Nov 2019

Shorter EPO opposition process requires new approaches from life sciences patentees

Strategies employed not only by rights owners but also by those opposing their grants will need to be recalibrated to reflect the new realities Read more

Insights

View all
29 Nov 2019

IP market news highlights

IAM’s biggest autumn reads Read more

24 May 2019

IP market news highlights

Some of the major news stories carried on the IAM platform from March to mid-May. Read more

1 Apr 2019

IP market news highlights

The big stories from the IAM platform in February and March. Read more